1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBundibugyo Virus Outbreak Response Vaccines (BundiVx) Program is sponsored by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
#### Looking for contract opportunity help?
* **Contract Opportunity Type:**Solicitation (Original) * **Original Published Date:**Jun 11, 2026 01:18 pm EDT * **Original Date Offers Due:**Jun 26, 2026 03:00 pm EDT * **Inactive Policy:**15 days after date offers due * **Original Inactive Date:**Jul 11, 2026 * **Original Set Aside:**No Set aside used * **Product Service Code:** AN23 - HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPERIMENTAL DEVELOPMENT * 541714 - Research and Development in Biotechnology (except Nanobiotechnology) * **Place of Performance:**Washington The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows: The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks.
Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10,000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical.
The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100,000 doses of cGMP CTM.
The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development. Please see the attachments for more information. **Questions are due June 16, 2026 by 12 p.
m. Eastern. Proposals are due by June 26 at 3 p.
m. Eastern. ** **Submission link:https://www.
rrpv. org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/** * O’NEILL HOUSE OFFICE BUILDING * **Jul 18, 2026 12:04 am EDT**Solicitation (Updated) * **Jun 17, 2026 03:43 pm EDT**Solicitation (Updated) * **Jun 17, 2026 03:41 pm EDT**Solicitation (Updated) * **Jun 11, 2026 01:18 pm EDT**Solicitation (Original)
According to the current listing, eligibility includes: Companies and organizations with expertise in vaccine development, manufacturing, regulatory engagement, nonclinical development, clinical evaluation, and outbreak response support, particularly those leveraging VSV vac…. Confirm the full requirements in the official notice before applying.
Bundibugyo Virus Outbreak Response Vaccines (BundiVx) Program is funded by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The joint NSF-NIH Smart Health and Biomedical Research solicitation supports high-risk, high-reward AI/data science work in health — $300K per year for four years, with 20+ NIH institutes participating. Here is how the program actually selects winners.
Read articleThe HHS Grants Policy Statement that took effect October 1, 2025 raised the micro-purchase threshold to $50,000, the single audit threshold to $1 million, and the de minimis indirect cost rate to 15 percent — quietly rewriting the operational rules for tens of billions of dollars in annual awards. Combined with full 2 CFR Parts 200 and 300 adoption and new MAHA-aligned program priorities, it is the biggest compliance shift for health grantees since Uniform Guidance arrived in 2013.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read article